CAR-T cell therapy for T-cell leukemia and lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell therapy (WU-CART-007) made from donor cells that target a protein called CD7 on cancer cells. It is for children and adults with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or is still present after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) that has not responded to treatment, come back, or still has signs of disease
- You are at least 6 months old
- Your vital organs (like kidneys and liver) are working well enough
- You are in fairly good physical shape (able to do daily activities with little or no help)
- You have not had any previous treatment that targets the CD7 protein
- You do not have severe graft-versus-host disease (a condition from past donor cell treatment) that needs strong medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This trial tests a new type of cell therapy (4SCAR7U) designed to target and kill cancer cells that carry a protein called CD7. It is for people with blood cancers that have not responded to other treatments.
This trial tests a new type of immune cell therapy (multi-CAR T cells) designed to target and kill cancer cells that have a marker called CD7. It may help people with certain blood cancers that have not responded well to other treatments.
This trial tests a personalized therapy where your child's own immune cells are modified to find and destroy cancer cells that carry a specific marker called CD7. It is for children and young adults whose T-cell leukemia or lymphoma has come back or not responded to standard treatments.
This trial tests a new cell therapy called CD7 CAR-T that targets a specific protein on your cancer cells. It is for people with T-cell lymphoma or T-cell leukemia that has not responded to other treatments or has come back.
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.